Investor Presentation Q1 2018 Audited Results
IV Appendix
Income Statement
In EGP
Gross Revenue
1
Net Revenue
2014
2015
2016
2017
4,301,516
5,439,119
7,372,467
9,818,405
1Q2017
1,953,189
1Q2018
2,958,341
YoY Change (1Q17-1Q18)
51%
4,197,376
5,327,728
7,205,983
9,586,344
1,906,746
2,881,099
Cost Of Revenue
(3,889,670)
Gross Profit
307,706
Gross Profit Margin
7.2%
(4,931,515)
396,213
7.3%
(6,636,864)
(8,759,914)
569,118
Selling, General & Administrative
(187,399)
Penalties On Returned Checks
1,792
EBITDA
122,099
(244,459)
3,296
155,050
7.9%
(346,502)
826,430
8.6%
(431,815)
(1,757,869)
148,878
7.8%
(95,903)
(2,665,364)
215,734
45%
7.5%
(125,923)
5,579
228,195
11,241
1,538
2,524
405,856
54,513
92,335
69%
EBITDA Margin
2.8%
2.9%
3.1%
4.1%
2.9%
3.2%
Depreciation & Amortization
(11,037)
(18,792)
(26,790)
(31,097)
(7,124)
(9,759)
EBIT
111,062
136,258
201,406
374,760
47,389
82,576
74%
EBIT Margin
2.6%
2.5%
2.7%
3.8%
2.5%
2.8%
Financial Expenses
(48,880)
(56,331)
(74,272)
(115,830)
(18,806)
(38,256)
Other Expenses
(7,408)
(5,912)
(3,173)
(37,559)
(56)
(11,781)
Other Income
7,481
1,873
9,137
6,326
344
6,368
EBT
62,255
75,888
133,098
227,697
28,871
38,906
35%
EBT Margin
1.4%
1.4%
1.8%
2.3%
1.5%
1.3%
Differed Tax
(2,379)
3,035
4,793
(600)
150
296
Income Tax
(22,335)
(21,564)
(36,143)
(56,960)
9,615
(11,249)
Net Profit
37,541
57,358
101,748
170,137
19,105
27,954
46%
Net Profit Margin
0.9%
1.1%
0.90%
1.10%
1.00%
1.00%
ibnsinapharma
Source: Company Management
(1) Gross revenue includes transportation revenue
27View entire presentation